Toward biosimilar monoclonal antibodies

To what extent is the existing framework for biosimilars in Europe likely to be applicable to monoclonal antibodies?

[1]  M. Clark,et al.  Antibody humanization: a case of the 'Emperor's new clothes'? , 2000, Immunology today.

[2]  N. Dovichi,et al.  Capillary electrophoresis for the analysis of biopolymers. , 2000, Analytical chemistry.

[3]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[4]  D. Harvey.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update covering the period 2001-2002. , 2006, Mass spectrometry reviews.

[5]  N. C. Price,et al.  The use of circular dichroism in the investigation of protein structure and function. , 2000, Current protein & peptide science.

[6]  K Wüthrich,et al.  NMR structure of the bovine prion protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[8]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[9]  Alain Van Dorsselaer,et al.  Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[11]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.